Edition:
United States

NantKwest Inc (NK.OQ)

NK.OQ on NASDAQ Stock Exchange Global Select Market

5.05USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$5.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
75,968
52-wk High
$8.43
52-wk Low
$2.71

Latest Key Developments (Source: Significant Developments)

Nantkwest announces publication of preclinical data of hank cell therapy
Tuesday, 25 Jul 2017 08:00am EDT 

July 25 (Reuters) - Nantkwest Inc ::Nantkwest announces publication of preclinical data of hank cell therapy in combination with checkpoint inhibitor avelumab providing strong rationale for advancement to human clinical trials.  Full Article

NantKwest expands nant cancer vaccine program
Tuesday, 6 Jun 2017 08:00am EDT 

June 6 (Reuters) - Nantkwest Inc ::NantKwest expands nant cancer vaccine program with additional clinical trials announced addressing multiple cancer types across all stages of disease.NantKwest Inc - expansion of company's existing nant cancer vaccine program in pancreatic cancer to target a number of additional tumor types.NantKwest - first combination off shelf NK, adaptive immunotherapy trial to be initiated for pancreatic, lung, breast and colon cancer, among others.  Full Article

Nantkwest and Nantcell announce FDA authorization for Nant Cancer vaccine clinical trials
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Nantkwest Inc :Nantkwest and nantcell announce fda authorization for the nant cancer vaccine clinical trials, the first novel combination of innate and adaptive immunotherapy in patients with pancreatic cancer.  Full Article

NantKwest and Viracta Therapeutics report series B financing
Tuesday, 4 Apr 2017 08:00am EDT 

NantKwest Inc : NantKwest and Viracta Therapeutics announce series b financing and immunotherapy partnership .NantKwest - co, Viracta Therapeutics announced initial closing of a series b preferred financing round of up to $18.4 million with co as lead investor.  Full Article

Nantkwest announces FDA grant of orphan drug designation
Monday, 20 Mar 2017 07:00am EDT 

Nantkwest Inc :Nantkwest announces FDA grant of orphan drug designation for the company's ank natural killer cell therapy in merkel cell carcinoma.  Full Article

Altor Bioscience and NantKwest announces co-development agreement
Tuesday, 4 Oct 2016 10:00am EDT 

NantKwest Inc: Financial terms of this co-development are not disclosed . Development agreement to advance innovative natural killer cell combination immunotherapies for the treatment of cancer . Altor and Co will exclusively collaborate on development of therapeutic applications combining altor's proprietary IL-15 superagonist .Altor, Co to also exclusively collaborate single-chain t cell receptor/IL-2 fusion protein products with Co's proprietary NK cell therapy platforms.  Full Article

BRIEF-Nantkwest announces publication of preclinical data of hank cell therapy

* Nantkwest announces publication of preclinical data of hank cell therapy in combination with checkpoint inhibitor avelumab providing strong rationale for advancement to human clinical trials Source text for Eikon: Further company coverage: